148 related articles for article (PubMed ID: 11959893)
21. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
22. Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.
Xiang Y; Li Q; Huang D; Tang X; Wang L; Shi Y; Zhang W; Yang T; Xiao C; Wang J
Exp Biol Med (Maywood); 2015 Feb; 240(2):160-8. PubMed ID: 25125500
[TBL] [Abstract][Full Text] [Related]
23. The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.
Salasznyk RM; Zappala M; Zheng M; Yu L; Wilkins-Port C; McKeown-Longo PJ
Matrix Biol; 2007 Jun; 26(5):359-70. PubMed ID: 17344041
[TBL] [Abstract][Full Text] [Related]
24. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Das A; Boyd N; Jones TR; Talarico N; McGuire PG
Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
[TBL] [Abstract][Full Text] [Related]
26. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
Mishima K; Mazar AP; Gown A; Skelly M; Ji XD; Wang XD; Jones TR; Cavenee WK; Huang HJ
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8484-9. PubMed ID: 10890917
[TBL] [Abstract][Full Text] [Related]
27. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
[TBL] [Abstract][Full Text] [Related]
28. Mitogenic signaling of urokinase receptor-deficient kidney fibroblasts: actions of an alternative urokinase receptor and LDL receptor-related protein.
Zhang G; Cai X; López-Guisa JM; Collins SJ; Eddy AA
J Am Soc Nephrol; 2004 Aug; 15(8):2090-102. PubMed ID: 15284295
[TBL] [Abstract][Full Text] [Related]
29. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
30. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis.
Gondi CS; Lakka SS; Yanamandra N; Siddique K; Dinh DH; Olivero WC; Gujrati M; Rao JS
Oncogene; 2003 Sep; 22(38):5967-75. PubMed ID: 12955075
[TBL] [Abstract][Full Text] [Related]
31. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
[TBL] [Abstract][Full Text] [Related]
32. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effect and mechanism of action of a tumor-targeting recombinant human tumor necrosis factor-α fusion protein mediated by urokinase.
Dai YC; Yang SM; Wang X; Zhou YJ; Hou G; Huang DN
Mol Med Rep; 2015 Jun; 11(6):4333-40. PubMed ID: 25672264
[TBL] [Abstract][Full Text] [Related]
34. Urokinase-mediated posttranscriptional regulation of urokinase-receptor expression in non small cell lung carcinoma.
Montuori N; Mattiello A; Mancini A; Taglialatela P; Caputi M; Rossi G; Ragno P
Int J Cancer; 2003 Jun; 105(3):353-60. PubMed ID: 12704669
[TBL] [Abstract][Full Text] [Related]
35. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
Stish BJ; Oh S; Vallera DA
J Neurooncol; 2008 Mar; 87(1):51-61. PubMed ID: 18084721
[TBL] [Abstract][Full Text] [Related]
36. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
Rabbani SA; Gladu J
Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.
Mohan PM; Chintala SK; Mohanam S; Gladson CL; Kim ES; Gokaslan ZL; Lakka SS; Roth JA; Fang B; Sawaya R; Kyritsis AP; Rao JS
Cancer Res; 1999 Jul; 59(14):3369-73. PubMed ID: 10416596
[TBL] [Abstract][Full Text] [Related]
38. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
40. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]